Investigational drug · Phase 2
TRX319
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "TRX319"
First trial start
2026
Mar 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TRX319", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis (SPMS)
- Multiple Sclerosis
- Multiple Sclerosis (MS) Primary Progressive
- Multiple Sclerosis (MS) Secondary Progressive
Approved drugs for the same conditions: Multiple sclerosis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "TRX319" as an intervention, largest first.
Tr1X, Inc.Industry
NCT07477639 · 39 participants (planned) · Start Mar 1, 2026 · Primary completion Aug 2028
Drug: TRX319; Bendamustine · For: Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis (SPMS); Multiple Sclerosis and 2 more
Sites: La Jolla, California; Kansas City, Kansas; Rochester, Minnesota · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Primary Progressive Multiple Sclerosis
- TolebrutinibSAR442168Phase 33 trials
Sanofi · Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- C-CAR168Phase 22 trials
AbelZeta Inc. · Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases
- SUN-627NEU-627, N-004850Phase 21 trial
Sundance Biosciences, Inc. · Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.